Effect of tacrine on in vivo release of dopamine and its metabolites in the striatum of freely moving rats

Journal of Pharmacology and Experimental Therapeutics

Volumn 277, Issue 2, 1996, Pages 917-922

  Warpman, Ulrika ^a,b,c   Zhang, Xiao ^b   Nordberg, Agneta ^b  

^a UPPSALA UNIVERSITY   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 5 HYDROXYINDOLEACETIC ACID; ATROPINE; DOPAMINE; HOMOVANILLIC ACID; MECAMYLAMINE; MUSCARINIC RECEPTOR BLOCKING AGENT; NICOTINIC RECEPTOR BLOCKING AGENT; PIRENZEPINE; TACRINE; TRITIUM;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CHOLINERGIC SYSTEM; CONTROLLED STUDY; DOPAMINE METABOLISM; DOPAMINERGIC SYSTEM; DRUG EFFECT; DRUG RECEPTOR BINDING; MALE; MICRODIALYSIS; NEUROPHARMACOLOGY; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0030431372     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. ADEM, A., JOSSAN, S S. AND ORELAND, L.: Tetrahydroaminoacridine inhibits human and rat brain monoamine oxidase. Neurosci. Lett. 14: 243-248, 1989.
2. ÅHLIN, A., NYBACK, H , JUNTHE, T., OHMAN, G. AND NORDGREN, I.: THA in Alzheimer's dementia: Clinical, biochemical and pharmacokinetic findings. In Alzheimer's disease: Basic mechanisms, diagnosis and therapeutic strategies, ed. by K. Iqbal, D. R C. McLachland, B Winblad and H M. Wisniewski, pp. 621-625, Wiley, New York, 1991.
3. ALHAINEX, K. AND RIEKKINEN, P. J.: Discrimination of Alzheimer patients responding to cholinesterase inhibitor therapy. Acta Neurol. Scand. Suppl. 149: 16-21, 1993.
4. BALDWIN, H. A., DE SOUZA, R. J., SARNA, G. S., MURRAY, T. K., GREEN, A R. AND CROSS, A. J.: Measurements of tacrine and monoamines in brain by in vivo microdialysis argue against release of monoamines by tacrine at therapeutic doses. Br. J. Pharmacol. 103: 1946-1950, 1991.
5. BENINGER, R. J.. The role of DA in locomotor activity and learning. Brain Res. Rev 6: 173-196, 1983.
6. BRAZELL, M. P., MITCHELL, S. N., JOSEPH, M H. AND GRAY, J. A.: Acute administration of nicotine increases the in vivo extracellular levels of dopamine, 3,4-dihydroxyphenylacetic acid and ascorbic acid preferentially in the nucleus accumbens of the rat: Comparison with caudate-putamen. Neuropharmacology 12: 1177-1185, 1990.
7. CLARKE, P. B. S. AND PERT, A.: Autoradiographic evidence for nicotine receptors on nigrostriatal and mesolimbic dopaminergic neurons. Brain. Res. 384: 355-358, 1985.
8. DAVIS, K. L., THAL, L J., GAMZU, E. R., DAVIS, C. S., WOOLSON, R. F., GRACON, S. I., DHACHMAN, D. A., SCHNEIDER, L. S., WHITEHOUSE, P. J., HOOVER, T. M., MORRIS, J. C., KAWAS, C. H., KNOPMAN, D. S., EARL, N. L., KUMAR, V., DOODY, R. S. AND THE TACRINE COLLABORATIVE STUDY GROUP.: A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. N. Engl. J. Med. 327: 1253-1259, 1992.
9. DE KLIPPEL, N., SARRE, S., EBINGER, G. AND MICHOTTE, Y.: Effect of M1- and M2-muscarinic drugs on striatal dopamine release and metabolism: An in vivo microdialysis study comparing normal and 6-hydroxydopamine-lesioned rats. Brain. Res. 630: 57-64, 1993.
10. + current. Eur. J. Pharmacol. 141: 153-159, 1987.
11. DRUKARCH, B., LEYSEN, J. E. AND STOOF, J. C.: Further analysis of the neuropathological profile of 9-amino-1,2,3,4-tetrahydroacridine (THA), an alleged drug for the treatment of Alzheimer's disease. Life Sci. 42: 1011-1017, 1988.
12. EAGGER, S. A., LEVY, R AND SAHAKIAN, B. J.: Tacrine in Alzheimer's disease. Lancet 337: 989-992, 1991.
13. EKMAN, L., LINDSTRÖM, B. AND ROXIN, P.: Determination of tacrine and the 1-hydroxy metabolite in plasma using HPLC. J. Chromatogr. 494: 387-402, 1989
14. FARLOW, M., GRACON, S. I., HERSHEY, L. A., LEWIS, K. W., SADOWSKY, C. H. AND DOLAN-URENO, J.: A controlled trial of tacrine in Alzheimer's disease J. Am. Med. Assoc. 268: 2523-2529, 1992.
15. FLYNN, D. AND MASH, D.: Multiple in vitro interactions with and differential in vivo regulation of muscarinic receptor subtypes by tetrahydroaminoacridine. J. Pharmacol. Exp. Ther. 250: 673-581, 1989.
16. FREEMAN, S. E. AND DAWSON, R. M.: Tacrine: A pharmacological review. Progr. Neurobiol. 36: 257-277, 1991.
17. GIORGUIEFF, M. F., LE FLOCH, M. L., GLOWINSKY, J. AND BESSON, M. J.: Involvement of cholinergic presynaptic receptors of nicotinic and muscarinic types in the control of the spontaneous release of dopamine from striatal dopaminergic terminals in the rat. J. Pharmacol. Exp. Ther. 200: 535-544, 1977.
18. GIORGUIEFF-CHESSELET, M. F., KEMEL, M. L., WANDSCHEER, D. AND GLOWINSKI, J.: Regulation of dopamine release by presynaptic nicotinic receptors in rat striatal slices: Effect of nicotine in a low concentration. Life Sci. 25: 1257-1262, 1979.
19. GRAY, E. G. AND WHITTAKER, V. P.: The isolation of nerve endings from brain in an electron microscopic study of cell fragments derived by homogenization and centrifugation. J. Anat 96: 79-88, 1962.
20. GRENHOFF, J. AND SVENSSON, T. H.: Nicotinic and muscarinic components of rat brain dopamine synthesis stimulation induced by physostigmine. NaunynSchmiedberg's Arch. Pharmacol. 346: 395-398, 1992.
21. HAIKALA, H. AND AHTEE, L.: Antagonism of the nicotine-induced changes of the striatal dopamine metabolism in mice by mecamylamine and pempidine. Naunyn-Schmiedberg's Arch. Pharmacol. 338: 169-173, 1988.
22. HARDY, J. A., ADOLFSSON, R., ALAFUZOFF, I., BUCHT, G., MARCUSSON, J., NYBERG, P., PERDAHL, E., WESTER, P. AND WINBLAD, B.: Transmitter deficits in Alzheimer's disease. Neurochem. Int. 7: 545-563, 1985.
23. HUNTER, A. J., MURRAY, T. K., JONES, J. A , CROSS, A. J. AND GREEN, A. R.: The cholinergic pharmacology of tetrahydroaminoacridine in vivo and in vitro. Br. J. Pharmacol. 98: 79-86, 1989.
24. HÅKANSSON, L.: Mechanisms of action of cholinesterase inhibitors in Alzheimer's disease. Acta Neurol. Scand. Suppl. 149: 7-9, 1993.
25. JOHANSSON, M., HELLSTRÖM-LINDAHL, E. AND NORDBERG, A.: Steady-state pharmacokinetics of tacrine in long-term treatment of Alzheimer patients Dementia 72: 111-117, 1995
26. JOSSAN, S. S., ADEM, A., WINBLAD, B. AND ORELAND, L.: Characterization of dopamine and serotonin uptake inhibitatory effects of tetrahydroaminoacridine in rat brain. Pharmacol. Toxicol. 71: 213-215, 1992.
27. KNAPP, M. J ., KNOPMAN, D. S., SOLOMON, P. R., PENDLEBURY, W. W., DAVIS, C. S. AND GRACON, S. I.: A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. J. Am. Med. Assoc. 271: 985-991, 1994.
28. LOIACONO, R. E. AND MITCHELSON, F. J.: Effect of nicotine and tacrine on acetylcholine release from rat cerebral cortical slices. Naunyn-Schmiedeberg's Arch. Pharmacol. 342: 31-35, 1990.
29. LOWRY, O H , ROSENBROUGH, N. J., FARR, A. L. AND RANDALL, R. J.: Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193: 265-275, 1951.
30. MCPHERSON, G. A.: Analysis of radioligand binding experiments: A collection of computer programs for the IBM PC. J. Pharmacol. Methods 14: 213-228, 1985.
31. 3H]AFDX 384 to cloned and native muscarinic receptors. J. Pharmacol. Exp. Ther. 259: 601-607, 1991.
32. NIELSEN, J. A., MENA, E. E., WILLIAMS, I. H., NOCERINI, M. R. AND LISTON, D.: Correlation of brain levels of 9-amino-1,2,3,4-tetrahydroaminoacridine (THA) with neurochemical and behavioral changes. Eur. J. Pharmacol. 173: 53-64, 1989.
33. NILSSON, L., ADEM, A., HARDY, J., WINBLAD, B. AND NORDBERG, A.: Do tetrahydroaminoacridine (THA) and physostigmine restore acetylcholine release in Alzheimer brains via nicotinic receptors? J. Neural. Transm. 70: 357-368, 1987.
34. NORDBEBG, A.: THA, a potential drug in the treatment of Alzheimer's disease. In Cholinesterases: Structure, Function, Mechanism, Genetics and Cell Biology, ed. by J. Massoulie, F. Baraou, E. Barnard, A. Chatonnet, B. Doctor and D. M. Quinn, pp. 327-331, American Chemical Society, Washington, 1991.
35. NORDBERG, A.: Biological markers and the cholinergic hypothesis in Alzheimer's disease. Acta Neurol. Scand. Suppl. 139: 54-58, 1992a.
36. NORDBERG, A.: Neuroreceptor changes in Alzheimer disease. Cerebrovasc. Brain Metab. Rev. 4: 303-328, 1992b.
37. NORDBERG, A., NILSSON-HAKANSSON, L., ADEM, A., LAI, Z. AND WINBLAD, B.: Multiple actions of THA on cholinergic transmission in Alzheimer brains. Prog. Clin. Biol. Res. 317: 1169-1178, 1989.
38. NORDBERG, A. AND WINBLAD, B. (EDITORS): Cholinesterase inhibitors in Alzheimer's disease. Acta Neurol. Scand. Sup. 149: 1-65, 1993.
39. OSBORNE, P. G., O'CONNOR, W. T. AND UNGERSTEDT, U.: Effect of varying the ionic concentration of a microdialysis perfusate on basal striatal dopamine levels in awake animals. J. Neurochem. 56: 452-456, 1991.
40. PAXINOS, G. AND WATSON, C.: The Rat Brain in Stereotaric Coordinates, Academic Press, New York, 1982.
41. RAITERI, M., LEARDI, R. AND MARCHI, M.: Heterogeneity of presynaptic muscarinic receptors regulating neurotransmitter release in the rat brain. J. Pharmacol. Exp. Ther. 228: 209-228, 1984.
42. RICHARDS, M H.: Rat hippocampal muscarinic autoreceptors are similar to the M2 (cardiac) subtype: Comparison with hippocampal M1, atrial M2 and ileal M3 receptors. Br. J. Pharmacol. 99: 753-761, 1990.
43. ROBINSON, T. N., DE SOUZA, R. J., CROSS, A. J. AND GREEN, A. R.: The mechanism of tetrahydroaminoacridine-evoked release of endogenous 5-hydroxytryptamine and dopamine from rat brain tissue prisms. Br. J. Pharmacol. 98: 1127-1136, 1989.
44. ROBINSON, T. E. AND WHISHAW, I. Q.: Normalization of extracellular dopamine in striatum following recovery from a partial unilateral 6-OHDA lesion of the substantia nigra: A microdialysis study in freely moving rats. Brain. Res. 450: 209-224, 1988.
45. SOININEN, H., UNNI, L. AND SCILLCUTT, S.: Effect of acute and chronic cholinesterase inhibition on biogenic amines in rat brain. Neurochem. Res. 15: 1185-1190, 1990.
46. STEVENS, D. R. AND COTMAN, C. W.: Excitatory actions of tetrahydro-9-aminoacridine (THA) on hippocampal pyramidal neurones. Neurosci. Lett. 79: 301-305, 1987.
47. SVENSSON, A.-L., ZHANG, X. AND NORDBERG, A.: Biphasic effect of tacrine on acetylcholine release in rat brain via M1 and M2 receptors. Brain Res., in press, 1996.
48. SZILAGYI, M. AND LAU, W.-M.: Interaction of tacrine at M1 and M2 cholinoceptors in guinea pig brain. Pharmacology (Basel) 47: 223-229, 1993.
49. TOTH, B., SERSHEN, H., HASHIM, A., VIZI, E. S. AND LAJTHA, A.: Effect of nicotine on extracellular levels of neurotransmitters assessed by microdialysis in various brain regions: Role of glutamic acid. Neurochem. Res. 17: 265-271, 1992.
50. WESTERINK, B. H. C., HOFSTEEDE, R. M., TUNTLER, J. AND DE VRIES, J. B.: Use of calcium antagonism for the characterization of drug-evoked dopamine release from the brain of conscious rats determined by microdialysis. J. Neurochem. 52: 722-729, 1989.
51. VIAUD, M. D. AND WHITE, N. M.: Dissociation of visual and olfactory conditioning in the neostriatum of rats. Behav. Brain. Res. 32: 31-42, 1989.
52. WHITE, N. M. AND VIAUD, M. D.: Localized intracaudate dopamine D2 receptor activation during the post-training period improves memory for visual or olfactory conditioned emotional responses in rats. Behav. Neurol. Biol 55: 255-269, 1991.
53. WISE, R. A.: Catecholamine theories of reward: A critical review. Brain Res. 152: 215-247, 1978.
54. XIAO, W.-B., NORDBERG, A. AND ZHANG, X.: Effect of in vivo microdialysis of 1,2,3,4-tetrahydro-9-aminoacridine (THA) on the extracellular concentration of acetylcholine in the striatum of anesthetized rats. J. Pharmacol. Exp. Ther. 265: 759-764, 1993.
55. XU, M., MIZOBE, F., YAMAMATO, T. AND KATO, T.: Differential effects of M1- and M2-muscarinic drugs on striatal dopamine release and metabolism in freely moving rats. Brain. Res. 495: 232-242, 1989.